3.10
1.64%
0.05
Dopo l'orario di chiusura:
3.10
Precedente Chiudi:
$3.05
Aprire:
$3.04
Volume 24 ore:
14,758
Relative Volume:
0.18
Capitalizzazione di mercato:
$137.24M
Reddito:
$18.11M
Utile/perdita netta:
$-18.95M
Rapporto P/E:
-3.5942
EPS:
-0.8625
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+40.27%
6M Prestazione:
+28.63%
1 anno Prestazione:
+129.63%
Adagene Inc Adr Stock (ADAG) Company Profile
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-06-25 | Iniziato | China Renaissance | Buy |
2021-03-08 | Iniziato | Goldman | Buy |
2021-03-08 | Iniziato | Jefferies | Buy |
2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Adagene to Participate in Investor Conferences in September, Business Wires News - AsiaOne
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - MSN
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance
Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart
Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow
Adagene Announces Updates to its Board of Directors - Quantisnow
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Quantisnow
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference - Quantisnow
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Quantisnow
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Quantisnow
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody ... - Quantisnow
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate - Quantisnow
Adagene (NASDAQ:ADAG) Given Buy Rating at HC Wainwright - Defense World
Adagene's (ADAG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 75.7% in May - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Drop in Short Interest - Defense World
Financial Analysis: Adagene Inc ADR (ADAG)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 26.5% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decrease in Short Interest - Defense World
Comparing Adagene (NASDAQ:ADAG) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
Adagene to Present at Investor Conferences in June - GlobeNewswire
Short Interest in Adagene Inc. (NASDAQ:ADAG) Expands By 6.3% - MarketBeat
Adagene Inc Adr Azioni (ADAG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):